Celgene Switzerland and BMS-backed precision cancer drug developer Repare Therapeutics added $33m to its IPO after its shares rose 65% post-offering.

Repare Therapeutics, the Canada-based oncology therapy developer that counts pharmaceutical firms Celgene and Bristol Myers Squibb (BMS) as investors, closed its initial public offering at $253m yesterday. The company raised $220m when it floated on the Nasdaq Global Select Market on Friday last week, upgrading the offering from 10 million to 11 million shares and…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.